Fig. 6
PCT sensitizes all cell lines to 5-FU. a All cell lines were subjected to co-treatment with TPCS2a and chloroquine (CQ) (10 μM). CQ was added together with TPCS2a the day before, and re-added after wash (total treatment time: 96 h). TPCS2a and light treatment (PCT) was performed as described in the PCI protocol in section 2.5 in Methods. Graphs show relative cell viability (%) following no light exposure, and 120 s light exposure. Reduction in cell viability (%) relative to untreated cells was measured by MTS assay. b Left; All cell lines were subjected to immunoblotting to detect total levels of LC3B-I and LC3B-II following co-treatment with TPCS2a and CQ (10 μM). CQ was added together with TPCS2a the day before, and re-added after wash (total treatment time: 96 h). Right; Quantification of LC3B-II signal intensity relative to intensity of Actin signal. Signal intensity is normalized to no treatment for each cell line. c All cell lines were subjected to co-treatment with TPCS2a and 5-FU (1 μg/ml). 5-FU was added together with TPCS2a the day before, and re-added after wash (total treatment time: 96 h). Graphs show relative cell viability (%) following no light exposure, and 120 s light exposure. Reduction in cell viability (%) relative to untreated cells (Ctrl) was measured by MTS assay. Representative data are shown. Error bars represent SD. Statistically significant difference between PCT and PCT + 5-FU in the 5-FU resistant lines and statisitically significant difference between 5-FU treatment and PCT + 5-FU treatment in the 5-FU sensitive cell lines is indicated by *. P < 0.05